Breaking News Instant updates and real-time market news.

CLDR

Cloudera

$19.10

2.02 (11.83%)

12:00
10/04/18
10/04
12:00
10/04/18
12:00

Cloudera rises 11.8%

Cloudera is up 11.8%, or $2.02 to $19.10.

  • 10

    Oct

  • 29

    Oct

CLDR Cloudera
$19.10

2.02 (11.83%)

10/04/18
10/04/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. AMC CUT TO SELL BY GOLDMAN: Goldman Sachs analyst Drew Borst downgraded AMC Networks (AMCX) to Sell from Neutral and lowered his price target for the shares to $61 from $64. The analyst expects AMC to underperform peers and his price target implies 8% downside to current levels. Weakness in National Networks advertising from "Walking Dead" ratings declines and heightened competition for scripted original series and viewers, as well as slowing revenue growth and higher content and marketing costs, create risk to consensus estimates, Borst said. SNAP TARGETS CUT BY EVERCORE, CITI: Evercore ISI analyst Anthony DiClemente lowered his price target for Snap (SNAP) to $7 from $9 given decelerating trends, management turnover, and competitive threats. He reiterated an Underperform rating on Snap's shares. Citi analyst Mark May kept a Sell rating on Snap, but again lowered his estimates -- also to $7 -- to reflect recent trends in user and average revenue per user growth, Q3 guidance and a projected 2018 exit growth rate. GOLDMAN SAYS FIREEYE STOCK COULD DOUBLE: Goldman Sachs analyst Gabriela Borges kept her Buy rating and $22 price target on FireEye (FEYE) after the company's annual Cyber Defense Summit. The analyst said the summit saw its strongest showing in three years and she believes Fireeye could see its shares double if it can gain just 200bps of market share in the endpoint and security information and event management, or SIEM, markets. Borges added that FireEye would have to improve its Helix business with "on premise integration" as well as "better messaging to the channel", expecting the company to proceed with a renewed scale push next year once the integration is complete. IBM STARTED WITH A SELL RATING: MoffettNathanson analyst Lisa Ellis initiated IBM (IBM) with a Sell rating and $150 price target. In late morning trading, IBM is down almost 1%. CLOUDERA GETS UPGRADED AFTER DEAL: Nomura Instinet analyst Christopher Eberle upgraded Cloudera (CLDR) to Buy from Neutral and raised his price target for the shares to $23 from $12. The analyst, who admits to being very surprised by the announced deal, believes the company's merger with Hortonworks (HDP) will be "highly accretive." DA Davidson analyst Rishi Jaluria upgraded Cloudera to Buy from Neutral and raised his price target to $27 from $15 while also affirming Hortonworks at Buy and raising its price target to $35 from $24. The analyst is positive on the merger's ability to reduce pricing pressure from the separation from the other Hadoop vendors, equip Cloudera to battle cloud data warehouse vendors like AWS (AMZN) Redshift, and accelerate innovation.
10/04/18
10/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. National Storage (NSA) upgraded to Buy from Hold at Jefferies with analyst George Hoglund saying he believes the recent weakness in the shares is overdone and presents a buying opportunity. 2. Cummins (CMI) upgraded to Overweight from Neutral at Piper Jaffray with analyst Alexander Potter saying his deep-dive analysis illuminates the likelihood of upside versus consensus estimates in the coming years. 3. Synnex (SNX) upgraded to Strong Buy from Buy at Needham with analyst Sean Hannon citing the company's business becoming "more diversified, experiencing healthy fundamental demand, and expanding its structural margin profile." 4. Cloudera (CLDR) upgraded to Buy from Neutral at DA Davidson and Nomura Instinet. 5. Washington Trust (WASH) upgraded to Buy from Hold at Sandler O'Neill withh analyst Mark Fitzgibbon saying management went out of their way to focus on their organic growth and "made a compelling argument that there is a dearth of good mid-size banks in New England." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/18
SBSH
10/04/18
NO CHANGE
SBSH
Combined Hortonworks, Cloudera could be worth $24-$31 per share, says Citi
Citi analyst Tyler Radke believes the merger between Hortonworks (HDP) and Cloudera (CLDR) is "strategically sound" and will create a company will "critical mass." The new company should be able to better leverage existing partnerships and capture significant cost/revenue synergies, Radke tells investors in a research note. He believes the combined company could be worth between $24 and $31 per share.
10/04/18
DADA
10/04/18
UPGRADE
Target $27
DADA
Buy
Cloudera upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Rishi Jaluria upgraded Cloudera (CLDR) to Buy from Neutral and raised his price target to $27 from $15 while also affirming Hortonworks (HDP) at Buy and raising its price target to $35 from $24 after the two companies announced an all-stock merger of equals yesterday. The analyst is positive on the merger's ability to reduce pricing pressure from the separation from the other Hadoop vendors, equip Cloudera to battle cloud data warehouse vendors like AWS (AMZN) Redshift, and accelerate innovation. Jaluria adds that even after the aftermarket gains in both companies' stocks, the market is likely undervaluing the combined company by assigning a 5-times enterprise value to expected forward revenue multiple, which is a "significant discount" to the peer group.

TODAY'S FREE FLY STORIES

EL

Estee Lauder

$201.74

22.48 (12.54%)

07:37
08/20/19
08/20
07:37
08/20/19
07:37
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

VVUS

VIVUS

$3.46

-0.02 (-0.57%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Hot Stocks
VIVUS says study shows addition of Qsymia to LSG surgery improved weight loss »

VIVUS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$125.55

0.73 (0.58%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 15

    Oct

TPIC

TPI Composites

$17.49

-0.2 (-1.13%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Upgrade
TPI Composites rating change  »

TPI Composites upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

PVTL

Pivotal Software

$13.85

-0.16 (-1.14%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

07:35
08/20/19
08/20
07:35
08/20/19
07:35
General news
Treasury Market Outlook: Treasuries are back in rally mode »

Treasury Market Outlook:…

DOW

Dow Inc.

$45.58

1.09 (2.45%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Hot Stocks
Dow Inc. to retrofit Louisiana cracker with FCDh technology to produce propylene »

Dow announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Oct

LULU

Lululemon

$178.63

0.83 (0.47%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
Lululemon analyst commentary  »

Lululemon earnings and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EVER

EverQuote

$22.18

0.88 (4.13%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
EverQuote analyst commentary  »

EverQuote price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$70.02

0.3 (0.43%)

07:33
08/20/19
08/20
07:33
08/20/19
07:33
Downgrade
Itron rating change  »

Itron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BIIB

Biogen

$235.61

4.05 (1.75%)

, NVTA

Invitae

$25.78

0.6 (2.38%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Biogen, Invitae announce availability of SMA STAT test »

Biogen (BIIB) and Invitae…

BIIB

Biogen

$235.61

4.05 (1.75%)

NVTA

Invitae

$25.78

0.6 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MBRX

Moleculin Biotech

$1.15

0.07 (6.48%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Moleculin Biotech receives Emory University CTRC approval for WP1066 trial »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$74.86

1.6 (2.18%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Hot Stocks
Qualcomm, LGE enter new global patent license agreement »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

CRM

Salesforce

$143.66

-0.23 (-0.16%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

HAIN

Hain Celestial

$21.88

0.14 (0.64%)

07:28
08/20/19
08/20
07:28
08/20/19
07:28
Downgrade
Hain Celestial rating change  »

Hain Celestial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 15

    Sep

VNO

Vornado

$61.34

0.14 (0.23%)

07:26
08/20/19
08/20
07:26
08/20/19
07:26
Downgrade
Vornado rating change  »

Vornado downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MKC

McCormick

$168.53

-1.585 (-0.93%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
McCormick rating change  »

McCormick downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$54.67

2.28 (4.35%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
Las Vegas Sands rating change  »

Las Vegas Sands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$207.98

4.335 (2.13%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Home Depot analyst commentary  »

Home Depot Q2 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CSCO

Cisco

$48.50

1.54 (3.28%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Cisco analyst commentary  »

Cisco 'sum of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 10

    Oct

  • 13

    Nov

RGNX

Regenxbio

$37.50

0.27 (0.73%)

, ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Upgrade
Regenxbio, Adverum Biotechnologies rating change  »

Regenxbio upgraded to…

RGNX

Regenxbio

$37.50

0.27 (0.73%)

ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 11

    Sep

SILK

Silk Road Medical

$40.85

0.28 (0.69%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Initiation
Silk Road Medical initiated  »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTX

Entera Bio

$2.30

-0.24 (-9.45%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Hot Stocks
Entera Bio to report results from Phase 2b study for oral PTH in September »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CPB

Campbell Soup

$43.17

0.53 (1.24%)

07:22
08/20/19
08/20
07:22
08/20/19
07:22
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 01

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.